Ceres Nanosciences reaches product development milestone for point-of-care Lyme disease test and closes on an additional $5.5M of Series A funding.

Ceres Nanosciences (Ceres) is announcing today that it has reached a key product development milestone for its Nanotrap® Lyme Antigen Test System. The Nanotrap® Lyme Antigen Test System will proceed into manufacturing and analytical performance testing this year and is on track for clinical study and FDA submission in 2019.